Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Adult immunization.

Treatment guidelines from the Medical Letter·2014
Same journal

Drugs for hypertension.

Treatment guidelines from the Medical Letter·2014
Same journal

Drugs for peptic ulcer disease GERD.

Treatment guidelines from the Medical Letter·2014
Same journal

Drugs for type 2 diabetes.

Treatment guidelines from the Medical Letter·2014
Same journal

Drugs for HIV infection.

Treatment guidelines from the Medical Letter·2014
Same journal

Drugs for lipids.

Treatment guidelines from the Medical Letter·2014

Related Experiment Video

Updated: May 23, 2026

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Drugs for tuberculosis

    Treatment Guidelines From the Medical Letter
    |March 28, 2012
    PubMed
    Summary

    Standard tuberculosis treatment involves daily isoniazid for nine months. Alternative regimens like weekly isoniazid and rifapentine for 12 weeks are available for certain patients, with directly observed therapy recommended for all active tuberculosis cases.

    Area of Science:

    • Infectious Diseases
    • Public Health
    • Pharmacology

    Background:

    • Tuberculosis (TB) remains a significant global health challenge.
    • Effective treatment regimens are crucial for disease eradication and preventing drug resistance.

    Purpose of the Study:

    • To outline current recommendations for the treatment of latent and active tuberculosis.
    • To provide guidance on managing drug-susceptible and drug-resistant TB.

    Main Methods:

    • Review of established treatment guidelines for tuberculosis.
    • Inclusion of standard and alternative therapeutic regimens.
    • Emphasis on directly observed therapy (DOT).

    Main Results:

    • Latent TB: Standard 9-month isoniazid or 12-week weekly isoniazid/rifapentine (DOT).

    More Related Videos

    System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
    09:57

    System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

    Published on: April 5, 2017

    Related Experiment Videos

    Last Updated: May 23, 2026

    A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
    10:29

    A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

    Published on: March 24, 2017

    System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
    09:57

    System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis

    Published on: April 5, 2017

  • Active TB: Initial 4-drug therapy (isoniazid, rifampin, pyrazinamide, ethambutol) until susceptibility known.
  • Drug-susceptible pulmonary TB: Continuation phase of 4-7 months with isoniazid and rifampin/rifapentine.
  • Drug-resistant TB: Minimum 4 drugs, 18-24 months, DOT, expert consultation.

    • Conclusions:

    • Directly observed therapy is recommended for all active TB patients to improve outcomes.
    • Treatment duration and drug selection vary based on TB type (latent, active, drug-resistant) and patient factors.
    • Adherence to prescribed regimens is critical for preventing treatment failure, relapse, and resistance.